 said it would be a ‘priority’. ){kind=link}
Cannabis rescheduling was thrown back into the spotlight last week as the new potential head of the Drug Enforcement Administration (DEA) said it would be a ‘priority’.
The DEA has the final say on the matter.
The DEA announced just last month that it had not made any progress since the suspension of its case. A formal hearing date to determine whether the DEA should be removed from the entire process had also yet to be set.
Washington has been moving with a breakneck pace, so that the DEA will not only be under a brand new administration, but also have a leader in the near future.
Terrance Col, the latest nominee of President Trump for DEA Administrator attended last week’s confirmation hearing before the Senate Judiciary Committee, during which he was grilled about his plans for this project.
He informed lawmakers that reviewing the stalled process would be ‘one of my first priorities’ if confirmed. But the law enforcement officer did not endorsing reclassification as proposed, saying that it was necessary to examine the issue more.
Cole acknowledged delays in the DEA’s ongoing review of cannabis’s status under federal law, stating that he was ‘not familiar exactly where we are, but I know the process has been delayed numerous times, and it’s time to move forward.’
When pressed by Sen. Alex Padilla, a Democrat from California, as to whether he would commit to seeing the process through, he declined to offer a concrete position, stating only that he ‘need(s) to understand more where the agencies are, and look at the science behind it,” he said, adding that he wanted to ‘listen to the experts’ before making a determination.
Cole may seem ambivalent about the matter, but if he sticks to his word and follows the original scientific recommendation of the United States Department of Health and Human Services, then there is a good chance that rescheduling will happen.
The Dale’s Report’s Speaking Trade Black Shane Pennington who represented the parties that called for interlocutory review in the podcast the previous week said this step was significant.
“Tell me the last time the head of the DEA said, ‘one of my priorities is going to be reviewing cannabis rescheduling,’ in any previous administration. This has never been done before. It is a great way to compare where we are now with four years ago.
“I’ve said it a couple of times that once the administration turns its attention to this, it can happen very quickly, if that’s their will and they want to do it, it’ll get done… What’s changed is that they You can also find out more about us on our website. “They turned their attention towards it.”
US Cannabis Roundtable also agreed with this view despite Cole’s indifference and disregard for marijuana.
We’re encouraged that President Trump has nominated Terry Cole as the new DEA director and acknowledged the fact that the Administration will look at cannabis rescheduling.
We see it as a signal to the American people that President Obama is willing to consider practical reforms. The president’s remarks about the topic during his campaign last autumn resonated with many, and now this new development indicates a willingness for him to carry through.
Pennington also suggested that, given the recorded history of the process so far, including the HHS recommendation, an LLC opinion, and a hearing which uncovered the apparent bias of the former DEA administrator Anne Milgramme, ‘it should be pretty easy for them to wrap this one up one way or another’.
The science and what is on record will help us move in the direction we want.
We have a brand new DEA Administrator coming under a newly elected administration. It’s clear that the scientific community has reviewed the evidence and reached a definitive conclusion.
It’s a real question: Are we going have a government that is willing to make this happen, and will we have a fair transparent process?” This process will not be derailed if these two factors are present.
Cannabis rescheduling was thrown back into the spotlight last week as the new potential head of the Drug Enforcement Administration (DEA) said it would be a ‘priority’.
The DEA is still in charge of the big rescheduling project, which would have moved cannabis from Schedule I to Schedule III.
The DEA announced just last month that it had not made any progress since the suspension of its case. A formal hearing date to determine whether the DEA should be removed from the entire process had also yet to be set.
Washington has been moving with a breakneck pace, so that the DEA will not only be under a brand new administration, but also have a leader in the near future.
Terrance Col, the latest DEA administrator nominee by President Trump, was grilled at his Senate Judiciary Committee hearings last week.
He informed lawmakers that reviewing the stalled process would be ‘one of my first priorities’ if confirmed. But the law enforcement officer did not endorsing reclassification as proposed, saying that it was necessary to examine the issue more.
Cole acknowledged delays in the DEA’s ongoing review of cannabis’s status under federal law, stating that he was ‘not familiar exactly where we are, but I know the process has been delayed numerous times, and it’s time to move forward.’
When pressed by Sen. Alex Padilla, a Democrat from California, as to whether he would commit to seeing the process through, he declined to offer a concrete position, stating only that he ‘need(s) to understand more where the agencies are, and look at the science behind it,” he said, adding that he wanted to ‘listen to the experts’ before making a determination.
Cole’s ambivalence on the subject is not a guarantee that a rescheduling will happen. However, if Cole sticks to his words and accepts the evidence provided by HHS in their original recommendation then there are good chances of a rescheduling.
The Dale’s Report’s Speaking Trade Black Shane Pennington who represented the parties that called for an interlocutory appel said on a podcast this week that it was a big step.
“Tell me the last time the head of the DEA said, ‘one of my priorities is going to be reviewing cannabis rescheduling,’ in any previous administration. This has never been done before. It is a great way to compare where we are now with four years ago.
“I’ve said it a couple of times that once the administration turns its attention to this, it can happen very quickly, if that’s their will and they want to do it, it’ll get done… What’s changed is that they You can also find out more about us on our website. “They turned their attention towards it.”
US Cannabis Roundtable also agreed with this view despite Cole’s indifference and disregard for marijuana.
We’re encouraged that President Trump has nominated Terry Cole as the new DEA director and acknowledged the fact that the Administration will look at cannabis rescheduling.
We see it as a signal to the American people that President Obama is willing to consider practical reforms. The president’s remarks about the topic during his campaign last autumn resonated with many, and now this new development indicates a willingness for him to carry through.
Pennington also suggested that, given the recorded history of the process so far, including the HHS recommendation, an LLC opinion, and a hearing which uncovered the apparent bias of the former DEA administrator Anne Milgramme, ‘it should be pretty easy for them to wrap this one up one way or another’.
The science and what is on record will help us move in a more positive direction.
Now we are getting a DEA administrator under a different administration. It’s clear that the scientific community has reviewed the evidence and reached a definitive conclusion.
The real question, then, is whether we will have an administration with the drive to make this happen and a transparent and fair process. This process will not be derailed if these two factors are present.
Cannabis Law Resources for Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certifications, permits, and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland